Reduced cavity formation technology for braces
WynnVision's patented dip-and-dry technology enhances O-rings used in braces, providing them with biocidal surfaces to prevent bacteria-induced cavities and white spot lesions. This innovative approach aims to improve dental health outcomes for orthodontic patients.
Overview
WynnVision LLC presents a cutting-edge technique designed to reduce cavities in patients with braces by treating brace O-rings with their patented dip-and-dry technology. This technology creates a biocidal surface on O-rings, effectively preventing the formation of cavities and white spot lesions caused by bacterial activity. Streptococcus mutans and Lactobacillus species, which metabolize sugars to produce harmful acids, are targeted by this innovation, offering a preventive measure against the dental challenges faced by orthodontic patients.
Technical specifications
Key features:
- Patented dip-and-dry technology confers long-lasting biocidal properties to O-rings
- Specifically targets bacteria responsible for cavity formation, such as Streptococcus mutans and Lactobacillus
- Aims to reduce the need for expensive remedial dental work by preventing cavities and white spot lesions
- Utilizes surface chemistry modification to inhibit bacterial growth and biofilm formation
Technology readiness level
This technology is at a Technology Readiness Level (TRL) of 4, indicating that it has been validated in a laboratory setting. Future validation efforts include in vitro testing to confirm antimicrobial effectiveness and partnerships with academic institutions and industry leaders to develop a commercialization plan.
About WynnVision LLC
WynnVision LLC is a biomedical company founded in 2016 that specializes in developing rapid, surface-modifying technologies for medical devices. By altering surface chemistry, their proprietary approach aims to kill bacteria on contact and inhibit biofilm formation, addressing significant healthcare challenges such as ventilator-associated pneumonia and catheter-related infections. The company provides a range of research services, including surface characterization, antimicrobial efficacy testing, and biocompatibility assessments, utilizing state-of-the-art equipment to perform evaluations consistent with ASTM guidelines.
These capabilities support the healthcare sector by providing innovative strategies to enhance patient safety and device longevity, specifically targeting infections that are difficult to diagnose and treat. Supported by multiple research grants from the National Institutes of Health and various innovation partnerships, WynnVision focuses on translating scientific research into practical, therapeutic solutions. Their work is central to reducing device-related complications, with ongoing projects aimed at improving the performance of indwelling catheters, endotracheal tubes, and surgical shunts.
delivered to your inbox.